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Cancer Surveillance Series: Non-Hodgkin’s Lymphoma
Incidence by Histologic Subtype in the United States
From 1978 Through 1995
Frank D. Groves, Martha S. Linet, Lois B. Travis, Susan S. Devesa
Background: Clinical investigations have shown prognostic
heterogeneity within the non-Hodgkin’s lymphomas (NHLs)
according to histology, but few descriptive studies have con-
sidered NHLs by subgroup. Our purpose is to assess the
demographic patterns and any notable increases in popula-
tion-based rates of different histologic subgroups of NHL.
Methods: Using data collected by the Surveillance, Epidemi-
ology, and End Results Program of the National Cancer In-
stitute, we calculated incidence rates for the major clinico-
pathologic categories of NHL by age, race, sex, geographic
area, and time period. Results: Among the 60 057 NHL cases
diagnosed during the period from 1978 through 1995, total
incidence (per 100 000 person-years) was 17.1 and 11.5
among white males and females, respectively, and 12.6 and
7.4 among black males and females, respectively. However,
rates for follicular NHLs were two to three times greater
among whites than among blacks, with little sex variation.
Blacks demonstrated much higher incidence than whites for
peripheral T-cell NHL, with the incidence rates higher in
males than in females. For other NHL subgroups, the inci-
dence rates for persons less than 60 years of age were gen-
erally higher among males than among females, with little
racial difference; at older ages, the rates were higher among
whites than among blacks, with little sex difference. High-
grade NHL was the most rapidly rising subtype, particularly
among males. Follicular NHL increased more rapidly in
black males than in the other three race/sex groups. Overall,
the broad categories of small lymphocytic, follicular, diffuse,
high-grade, and peripheral T-cell NHL emerged as distinct
entities with specific age, sex, racial, temporal, and geo-
graphic variations in rates. Conclusions: Findings from our
large, population-based study reveal differing demographic
patterns and incidence trends according to histologic group.
Future descriptive and analytic investigations should evalu-
ate NHL risks according to subtype, as defined by histology
and new classification criteria. [J Natl Cancer Inst 2000;92:
1240–51]
With an estimated 54 900 new cases projected for the year
2000 in the United States (1), non-Hodgkin’s lymphoma (NHL)
is now the fifth most common malignant neoplasm after cancers
of the breast, prostate, lung, and colon. Although NHL incidence
and mortality rates worldwide have risen rapidly during the past
few decades (2–4), the reasons for these increases are largely
unknown. While risk factors for selected types of NHL have
been identified, etiologic influences for most types of NHL are
unknown.
There are few comprehensive evaluations of the descriptive
epidemiology of NHL that take subtype into account. These
types of studies have been limited by the rarity of many NHL
subtypes, the lack of a large, population-based incident case
group identified over a long interval and categorized according
to a standardized approach, and problems with reproducibility of
NHL classification as documented in population-based and
clinical settings. Using the Iowa Surveillance, Epidemiology,
and End Results (SEER)1 Program registry data, researchers
found 57%–63% agreement among expert pathologists in clas-
sifying NHL cases according to the Working Formulation (WF)
(5) and 77% agreement among SEER Program coders in assign-
ing the International Classification of Diseases for Oncology
(ICD-O) codes to cases (6). Investigators from the Eastern Co-
operative Oncology Group were unable to classify 4.3% of the
NHL cases using WF categories but found similar levels of
agreement (61%) among expert pathologists (7) as did Dick et
al. (5).
While recognizing these limitations, we exploited a singular
opportunity to examine the patterns and trends of NHL subtypes
in a large population according to a standardized classification
scheme.
METHODS
Ascertainment of Cases
The SEER Program of the National Cancer Institute has compiled incidence
data since 1973 from population-based cancer registries in five states (Connecti-
cut, Hawaii, Iowa, New Mexico, and Utah) and in four metropolitan areas
(Atlanta, GA; Detroit, MI; San Francisco, CA; and Seattle, WA) that make up
approximately 10% of the U.S. population (8). Data routinely collected by par-
ticipating cancer registries include anatomic site and histology of cancer as well
as patient demographic characteristics, such as age, sex, race, and vital status.
Classification of Cases
Each SEER registry codes all cancers, including NHL, according to a standard
classification scheme by use of information from diagnostic pathology reports in
medical records. NHL cases diagnosed from 1973 through 1977 were classified
according to the Manual of Tumor Nomenclature and Coding (MOTNAC) (9).
Beginning in 1978, the more detailed scheme of the ICD-O (10) was adopted to
code all NHLs and other cancers registered by the SEER Program. Since 1992,
the SEER Program has coded NHL and other newly diagnosed cancers using the
ICD-O, 2nd Edition (ICD-O-2) (11). The SEER Program used a computerized
algorithm to recode the incident cancers diagnosed before 1992 according to
ICD-O-2. Since the NHL categories used in MOTNAC were too few and too
vague for precise classification, our analysis begins with cases initially diag-
nosed in 1978, the first year ICD-O was used, and includes 60 057 cases diag-
nosed through 1995, the most recent available year.
The SEER Program also has used the ICD-O-2 morphology codes to recat-
egorize the NHL cases according to the WF, an NHL classification scheme
developed for prognostic purposes (12). There are 10 subtypes (designated A–J)
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in the WF; based on differences in survival, these have been designated as low
grade (subtypes A–C), intermediate grade (subtypes D–G), and high grade (sub-
types H–J). Overlaid on this clinical grading scheme is the morphologic distinc-
tion among the follicular (B–D), diffuse (E–G), and high-grade (H–J) subtypes.
Most ICD-O-2 designations correspond to one of the 10 subtypes (13), although
several ICD-O-2 categories, such as follicular, NOS (not otherwise specified),
diffuse, NOS, and high-grade, NOS, are insufficiently precise to allow for de-
tailed classification using A–J. Therefore, we combined these categories with the
10 WF subtypes to derive six major types, as shown in Table 1: small lympho-
cytic NHL, follicular NHL, diffuse NHL, high-grade NHL, peripheral T-cell
NHL, and NHL, NOS.
Calculation and Presentation of Rates
Subtype-specific NHL incidence rates were calculated for population sub-
groups according to age, sex, and race, as well as registry and time period.
Age-specific rates were calculated for 18 5-year age groups, expressed as new
cases per 100 000 person-years, and then directly age-adjusted to the 1970 U.S.
standard population. Age-adjusted, age-specific incidence rates were also ascer-
tained for eight broader age groups (0–14, 15–24, 25–34, 35–44, 45–54, 55–64,
65–74, and 75 years).
The figures are presented using uniform semilogarithmic scales so that rates
of change can be compared (14). Percent increases for total NHL and for each
subtype were calculated by comparing the rates for three 6-year time periods:
from 1978 through 1983, from 1984 through 1989, and from 1990 through 1995.
For all extranodal NHL cases, we examined incidence by anatomic site of origin
and histologic subtype over the entire 18-year period because of the rarity of
NHL in many of the extranodal categories. The distribution of NHL cases
classified by immunophenotype (B cell versus T cell versus other and unspeci-
fied immunophenotypes) was evaluated for the period from 1990 through 1995,
since the proportion of NHL cases with immunophenotype recorded in the SEER
files before 1990 was small.
Statistical Considerations and Comparisons of Rates
This study represents a descriptive exploratory analysis looking for patterns,
without any a priori hypotheses. The variance of an incidence or mortality rate
can be approximated by dividing the rate (number of new cases or deaths/
100 000 person-years) squared by the number of events (number of new cases or
deaths, respectively) on which the rate was based. Differences in rates and ratios
of rates can be tested by calculating approximate confidence intervals (CIs)
according to (15). If c the number of cases, p the number of people in the
population, and the rate r  c/p, then the 95% CI for the rate is r ± 1.96 *
SQRT[var (r)]  r ± 1.96 * r/SQRT[c]; the 95% CI for a rate difference is (r1
− r2) ± 1.96 * SQRT[var (r1) + var (r2)]  (r1 − r2) ± 1.96 * SQRT[r1*r1/c1
+ r2*r2/c2]; and the 95% CI for a rate ratio is exp[ln(r1/r2) ± 1.96 * SQRT (1/c1
+ 1/c2)].
RESULTS
Age-Adjusted Incidence Rates by Subtype, Race, and Sex
During the period from 1978 through 1995, 60 057 cases of
NHL were diagnosed among residents of the nine SEER areas:
53 171 among whites, 3584 among blacks, 2831 among persons
of other specified races (2226 Asians, 232 Hawaiians, 138
American Indians or Alaska Natives, 31 Pacific Islanders, and
204 others), and 471 among persons of unknown race. Incidence
rates for blacks and whites are shown in Table 2; incidence rates
for persons of other races are not included because of small
numbers of cases and difficulties in estimating intercensal popu-
lation denominators.
Across all four race/sex groups, diffuse NHL accounted for
39%–44% of NHL, and small lymphocytic NHL accounted for
9%–10%. The proportion of NOS cases was lower among whites
(14% for males and 13% for females) than among blacks (20%
for males and 18% for females). The total NHL rates were
40%–70% higher among whites than among blacks and among
males than among females. The male-to-female incidence rate
ratios were greater than 2 for high-grade and peripheral T-cell
NHL and greater than 1 for most other histologic types, but they
were close to unity for follicular NHL among whites. The white-
to-black incidence rate ratios were around 2–3 for follicular
NHL and ranged between 1 and 2 for most other major types but
were less than 1 for peripheral T-cell NHL.
Age-Specific Incidence Rates
Total NHL incidence rates (Fig. 1) increased monotonically
with age in all race and sex subgroups. No racial differences
were observed in the age-specific incidence curves until age 45
years for males and age 35 years for females; after these ages,
the rates were higher in whites than in blacks. Age-specific
incidence rates were higher in males than in females at all ages,
regardless of race. Rates for NHL, NOS, increased with age,
with higher rates among blacks than among whites for ages
15–64 years among males and for ages 15–54 years among
females; rates were notably higher among males than among
females for ages 15–64 years and, subsequently, there was little
Table 1. Classification of non-Hodgkin’s lymphoma*
Major types Working Formulation subtypes ICD-O-2 codes
Small lymphocytic A: Small lymphocytic 9670, 9671
Follicular B: Follicular small 9693, 9694, 9695, 9696
C: Follicular mixed 9691, 9692
D: Follicular large 9697, 9698
(Follicular, NOS)† 9690
Diffuse E: Diffuse small 9672, 9673, 9674
F: Diffuse mixed 9675, 9676
G: Diffuse large 9593, 9680, 9681, 9682, 9683
(Diffuse, NOS)† 9595, 9677, 9688, 9710, 9711, 9715
High-grade H: Immunoblastic 9684
I: Lymphoblastic 9685
J: Small noncleaved 9686, 9687
(High-grade, NOS)† 9594
Peripheral T-cell 9700, 9701, 9702, 9703, 9704, 9705, 9706, 9707, 9708, 9709, 9712, 9713, 9714
NOS 9590, 9591, 9592
*ICD-O-2  International Classification of Diseases for Oncology, 2nd edition (11); NOS  not otherwise specified.
†Subtypes within parentheses were not categorized to a specific subtype A–J but were included in the respective major type.
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difference in rates according to sex among persons aged 65 years
or older.
Peripheral T-cell NHL increased with age and was more com-
mon among blacks than among whites at almost all ages, al-
though the male excess among blacks became apparent only
after the age of 35 years. Small lymphocytic NHL rates in-
creased exponentially with age to reach more than 100-fold
greater for all whites over the age of 75 years than for those aged
25–34 years, and the rates showed little racial disparity. For
follicular NHL and for its subtypes, rates rose with age, although
sex differences were small, and whites of both sexes had higher
rates than blacks at most ages.
Diffuse NHL rates increased with age but varied little be-
tween the races among the middle-aged groups; rates were
higher among whites at older ages. High-grade NHL was the
only type to occur notably among children. The excess in males
of high-grade NHL, mostly small noncleaved NHL, was par-
ticularly marked under the age of 50 years; no consistent racial
disparity was evident. In contrast to the more rapid rise in inci-
dence occurring with increasing age for all other subtypes of
NHL, the age-specific incidence of small noncleaved NHL in-
creased relatively slowly with age, and lymphoblastic NHL ac-
tually showed a “U-shaped” age-specific incidence curve.
(High-grade NHL rates by subtype among females were so low
that they are not shown in Fig. 1.) Thus, similarities in the shapes
of the age-specific incidence curves of the subtypes within each
major type support the aggregation of the three follicular sub-
types, the three diffuse subtypes, and the three high-grade sub-
types.
Regional Variation in Age-Adjusted Incidence Rates
Among Whites
Data presented (Table 3) are limited to whites because the
numbers of NHL cases among blacks were too small to allow for
meaningful geographic comparisons. Among whites, the geo-
graphic patterns differ according to sex, and the registry-specific
data are listed within sex in decreasing order of total NHL rate.
For males, age-adjusted incidence rates in San Francisco were
higher than the SEER rates for total NHL and for every major
subtype except small lymphocytic NHL. Rates in New Mexico
were lower than the SEER rates for total NHL and for every
major subtype as well. Male total NHL incidence rates were
82% higher in San Francisco than in New Mexico; the San
Francisco excess was largely attributable to the elevated rates for
diffuse NHL (76% higher in San Francisco than in New Mexico)
and high-grade NHL (almost twice as high in San Francisco than
in New Mexico).
Among females, age-adjusted incidence rates in both Detroit
and Connecticut were higher than the SEER rates for total NHL
and for high-grade NHL in Detroit and for small lymphocytic
NHL in Connecticut, although these differences were small.
Rates for females in New Mexico were lower than the SEER
rates for total NHL and for the small lymphocytic, follicular, and
diffuse subtypes. With total NHL incidence in Detroit being only
33% higher than in New Mexico, it is clear that there is less
variation in NHL incidence among females than among males.
In particular, the rates among white females in San Francisco
were close to the SEER rates for most NHL subtypes, in contrast
to the marked excesses observed there among white males.
Site Distribution of Extranodal Lymphomas by Subtype
Approximately 27% of all NHL cases were extranodal (Table
4); for most histologic groups, this fraction ranged between 21%
and 33%, with two notable exceptions: 82% of peripheral T-cell
NHL cases were extranodal, almost all of which involved the
skin, and only 9% of follicular NHL cases were extranodal.
Almost half of all extranodal NHL cases were of a diffuse his-
Table 2. Non-Hodgkin’s lymphoma cases and incidence rates* in nine SEER areas (from 1978 through 1995) by race, sex, and histology†
Histology
White males White females Black males Black females
Rate ratios
White males/
white females
Black males/
black females
White males/
black males
White females/
black femalesNo. Rate No. Rate No. Rate No. Rate
Total 28 635 17.1 24 536 11.5 2114 12.6 1470 7.4 1.5 1.7 1.4 1.6
Small lymphocytic
A: Small lymphocytic 2617 1.6 2342 1.1 205 1.4 148 0.8 1.5 1.8 1.1 1.4
Follicular 4969 3.0 5451 2.7 205 1.3 176 0.9 1.1 1.5 2.3 3.1
B: Follicular small 2591 1.6 2685 1.3 93 0.6 72 0.4 1.2 1.6 2.6 3.6
C: Follicular mixed 1307 0.8 1582 0.8 48 0.3 54 0.3 1.0 1.1 2.5 2.9
D: Follicular large 642 0.4 751 0.4 38 0.2 26 0.1 1.1 1.6 1.7 2.6
(Follicular, NOS)‡ 429 0.3 433 0.2 26 0.2 24 0.1 1.2 1.5 1.6 1.9
Diffuse 12 157 7.3 10 930 5.0 831 5.1 623 3.2 1.4 1.6 1.4 1.6
E: Diffuse small 2365 1.5 1975 0.9 146 1.0 126 0.7 1.6 1.5 1.5 1.4
F: Diffuse mixed 1472 0.9 1512 0.7 111 0.7 98 0.5 1.3 1.4 1.3 1.4
G: Diffuse large 8133 4.8 7291 3.4 562 3.3 391 1.9 1.4 1.7 1.5 1.7
(Diffuse, NOS)‡ 187 0.1 152 0.1 12 0.1 8 0.0 1.6 2.0 1.4 1.8
High-grade 3408 2.0 1776 0.9 278 1.5 129 0.6 2.3 2.3 1.4 1.3
H: Immunoblastic 1825 1.0 1121 0.5 148 0.8 88 0.4 2.0 1.9 1.3 1.2
I: Lymphoblastic 377 0.2 173 0.1 43 0.2 15 0.1 2.6 2.7 1.2 1.3
J: Small noncleaved 1183 0.7 462 0.2 84 0.4 25 0.1 3.1 3.4 1.8 1.9
(High-grade, NOS)‡ 23 0.0 20 0.0 3 0.0 1 0.0 1.0 2.0 0.5 1.0
Peripheral T-cell 1346 0.8 784 0.4 168 1.1 126 0.6 2.1 1.8 0.8 0.6
NOS 4138 2.4 3253 1.4 427 2.4 268 1.3 1.7 1.8 1.0 1.1
*All rates are per 100 000 person-years at-risk, age-adjusted to the 1970 U.S. population.
†SEER  Surveillance, Epidemiology, and End Results Program; NOS  not otherwise specified.
‡Subtypes within parentheses were not categorized to a specific subtype A–J but were included in the respective major type.
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tology. The majority of the NHLs arising from the following
sites had a diffuse histologic pattern: stomach, small intestine,
colon, soft tissue, thyroid, and testis. Most extranodal NHLs
were concentrated in just four sites: skin, stomach, brain, and
small intestine. About half of cerebral NHLs were of an unspeci-
fied histology.
Immunophenotype Distribution by Subtype
In recent years, the SEER Program has collected immuno-
phenotypic data for NHL. Before 1990, fewer than one fourth of
all NHL cases in the SEER database had immunophenotypic
data recorded. Between 1990 and 1995, almost 61% of all NHL
cases still were recorded as unknown immunophenotype, about
34% were B-cell type, and approximately 6% were T-cell type
(Table 5). During the period from 1990 through 1995, the pro-
portion of cases not specified as T or B cell ranged by subtype
from 36% to 100%. The percentage of NHL cases of unknown
phenotype decreased from 68% in 1990 to 53% in 1995.
Trends in Incidence of NHL
During the period from 1978–1983 to 1990–1995, age-
adjusted total NHL incidence rates (Fig. 2) increased by 77% in
black males and by 53% in white males but only by 39% and
33% among black and white females, respectively. When a more
detailed evaluation was conducted to compare the change in
incidence among three time periods (1978–1983, 1984–1989,
Fig. 1. Incidence rates for non-
Hodgkin’s lymphoma in the nine
Surveillance, Epidemiology, and
End Results areas for the period
from 1978 through 1995 by age
group 0–14, 15–24, 25–34, . . .,
65–74, greater than or equal to
75 years of age. Note: each rate
was plotted at the mid-point of
the age interval. Data were not
shown for females in panels I
and J because of small numbers
and low rates.
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and 1990–1995), the percentage increase slowed from 32%
(from 1978–1983 to 1984–1989) to 16% (from 1984–1989 to
1990–1995) among white males, from 20% to 11% among white
females, and from 19% to 17% among black females; only
among black males did the percentage increase accelerate, from
21% to 46%.
High-grade NHL increased most rapidly between 1978–1983
and 1990–1995, tripling among males and doubling among fe-
males. Immunoblastic NHL was the fastest-growing high-grade
subtype, followed by small noncleaved and lymphoblastic NHL
(in that order). Other histologic types increased more slowly.
Small lymphocytic NHL increased by 36%–44% in all four race/
sex groups. Follicular NHL remained stable among black fe-
males and increased only 16%–22% among whites from 1978 to
Table 4. Non-Hodgkin’s lymphoma cases and incidence rates* (all races and both sexes) in nine SEER areas (from 1978 through 1995)
by histology and site†
Site
No. of
cases
Incidence rates
Total‡ Small lymphocytic Follicular Diffuse High-grade Peripheral T-cell NOS
All sites 60 057 13.5 1.3 2.6 5.8 1.4 0.6 1.9
Nodal 43 677 9.9 1.0 2.4 4.2 1.0 0.1 1.3
Extranodal 16 380 3.7 0.3 0.2 1.7 0.4 0.5 0.6
Skin 2969 0.7 <0.1 <0.1 0.1 <0.1 0.5 0.1
Stomach 2717 0.6 0.1 <0.1 0.4 <0.1 <0.1 0.1
Brain 1569 0.3 <0.1 <0.1 0.1 0.1 <0.1 0.2
Small intestine 1185 0.3 <0.1 <0.1 0.1 0.1 <0.1 <0.1
Lung 647 0.1 <0.1 <0.1 0.1 <0.1 <0.1 <0.1
Soft tissue 639 0.1 <0.1 <0.1 0.1 <0.1 <0.1 <0.1
Colon 596 0.1 <0.1 <0.1 0.1 <0.1 <0.1 <0.1
Eye 534 0.1 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1
Thyroid 502 0.1 <0.1 <0.1 0.1 <0.1 <0.1 <0.1
All other sites 5022 1.1 0.1 0.1 0.6 0.1 <0.1 0.2
*All rates are per 100 000 person-years at-risk, age-adjusted to the 1970 U.S. population. Note: No rates were based on zero cases.
†SEER  Surveillance, Epidemiology, and End Results Program; NOS  not otherwise specified.
‡Because of rounding, the total rate may not equal the sum of the subtype rates.
Table 3. Non-Hodgkin’s lymphoma cases and incidence rates* among whites (from 1978 through 1995) by histology and SEER area†
Sex and
registry‡
No. of
cases
Incidence rates
% NOS
of totalTotal§ Small lymphocytic Follicular Diffuse High-grade Peripheral T-cell NOS
Males
San Francisco–Oakland (CA) 5700 22.2 1.6 3.4 9.0 3.4 1.2 3.7 16.5
Seattle–Puget Sound (WA) 4420 17.4 1.7 3.1 7.1 1.7 0.9 3.0 17.0
Metropolitan Detroit (MI) 4458 16.8 1.8 3.0 6.9 1.7 0.8 2.6 15.5
Connecticut 4610 16.5 1.8 2.7 7.0 1.8 0.9 2.3 13.8
Hawaii 418 16.3 1.2 2.6 6.9 3.2 0.4 2.0 12.5
Iowa 4368 16.2 1.6 3.6 7.9 1.3 0.6 1.2 7.6
Metropolitan Atlanta (GA) 1689 15.7 1.6 2.7 7.2 1.7 0.7 1.7 10.9
Utah 1628 14.8 1.4 2.2 6.3 2.2 0.5 2.2 15.2
New Mexico 1344 12.2 0.9 2.4 5.1 1.7 0.6 1.6 13.1
Nine SEER areas 28 635 17.1 1.6 3.0 7.3 2.0 0.8 2.4 14.1
Females
Metropolitan Detroit 4212 12.1 1.1 2.9 5.0 1.0 0.4 1.8 14.5
Connecticut 4483 12.0 1.2 2.6 5.1 1.0 0.4 1.7 13.9
Iowa 4349 11.8 1.0 3.0 6.0 0.7 0.3 0.8 6.9
San Francisco–Oakland 3685 11.8 1.1 2.8 5.1 0.9 0.6 1.3 10.9
Seattle–Puget Sound 3512 11.3 1.0 2.8 4.8 0.7 0.4 1.7 14.7
Metropolitan Atlanta 1477 11.0 1.1 2.6 5.0 0.7 0.3 1.3 11.5
Utah 1376 10.5 0.9 1.9 4.6 1.0 0.4 1.8 16.7
Hawaii 244 10.0 1.1 2.5 4.2 1.0 0.3 0.9 9.2
New Mexico 1198 9.1 0.8 2.1 3.6 1.0 0.3 1.4 14.8
Nine SEER areas 24 536 11.5 1.1 2.7 5.0 0.9 0.4 1.4 12.5
*All rates are per 100 000 person-years at-risk, age-adjusted to the 1970 U.S. population.
†SEER  Surveillance, Epidemiology, and End Results Program; NOS  not otherwise specified.
‡Registries listed within sex in decreasing order of total rate.
§Because of rounding, the total rate may not equal the sum of the subtype rates.
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1995 but increased among black males by 25% between 1978–
1983 and 1984–1989, followed by an even larger increase of
42% between 1984–1989 and 1990–1995, for a total increase of
77%. Diffuse NHL rose by 30%–41% among males versus
19%–25% among females, with the greatest increase (50%–
91%) seen for diffuse large NHL. Diffuse small NHL was the
only subtype that declined (42%–47%) in all four race/sex
groups. Although incidence rates for peripheral T-cell NHL re-
mained higher among blacks than among whites, the rate of
increase was greater among whites (134%–161%) than among
blacks (52%–84%), narrowing the racial gap. NHL, NOS, in-
creased faster among males (128%–160%) than among females
(42%–73%), with little difference by race within sex.
DISCUSSION
Our study is distinct in analyzing more than 60 000 NHL
cases from a well-defined population simultaneously by age,
sex, race, and histologic type, as well as by geographic area and
time period of diagnosis. Major histologic categories of NHL
differ in key characteristics. Follicular NHL is twice as common
in whites as in blacks, but the male/female ratio is close to unity;
however, the disproportionately rapid increase from 1978
through 1995 among black males has tended to increase the
male/female ratio among blacks while reducing the white/black
ratio among males. Diffuse NHL occurs more frequently among
males than among females at middle ages and among whites
than among blacks at older ages. Diffuse NHL accounts for close
to half of the extranodal NHL, arising in the stomach, small
intestine, colon, soft tissue, and thyroid. The incidence of high-
grade NHL tripled among males and doubled among females
from 1978 through 1995. High-grade and peripheral T-cell NHL
are both twice as common in males as in females. Peripheral
T-cell accounts for 5%–10% of NHL in all age groups and is
unique among subtypes in being more common among blacks
than among whites. The subtype-specific NHL incidence pat-
terns may reflect the influence of different etiologic as well as
host factors as summarized below.
Risk Factors Related to Functional Immunologic
Abnormalities
NHL is a malignancy of lymphocytes, the primary effector
cells of the immune system. Disorders characterized by severe
immunologic compromise or even moderately serious immune
dysfunction have been consistently linked with excesses of NHL
(see below). Conversely, selected exposures that may be asso-
ciated with low-to-moderate immune effects, such as infections,
vaccinations, allergies, medications, and other influences, may
be inversely associated with NHL risk (16,17).
Therapeutic immunosuppression. Increased rates of NHL
have been described in a clinical series of patients treated with
immunosuppressive drugs following transplantation with donor
kidneys (35- to 59-fold) (18–20) or heart or bone marrow (68- to
336-fold) (21,22). The cumulative incidence of NHL, however,
is only about 1% 10 years after bone marrow transplantation
(23). NHL after solid organ transplants tends to be of diffuse
large or immunoblastic histology (24), and extranodal involve-
ment is common (25). Despite the dramatic increase from 12 788
organ transplants in the United States in 1988 to 20 354 in 1996
(26), transplant-associated NHL accounts for a minuscule frac-
tion of this malignancy.
Autoimmunity. Relative risks ranging from 2 to 44 for NHL
have been observed in patients with celiac disease or dermatitis
herpetiformis (27,28), systemic lupus erythematosus (29,30),
sicca syndrome (31,32), and rheumatoid arthritis (33–38), with
lower risks in population-based studies (30,37,38), although data
on histologic type of NHL are limited. NHL-related autoimmune
diseases are unlikely to contribute meaningfully to rising secular
trends in NHL, since the incidence of autoimmune disorders has
either not increased (39) or risen only modestly (40) over time.
Congenital immunodeficiency. Data from the Immunodefi-
ciency Cancer Registry (41) are consistent with notably in-
creased risks of NHL among children with congenital X-linked
immunodeficiency and severe combined system immunodefi-
ciency, as well as with excesses in young persons with ataxia-
telangiectasia or Wiskott–Aldrich syndrome. The rarity of con-
genital immunodeficiency disorders, however, precludes a
substantial contribution to the increasing incidence of NHL, and
subtypes of lymphoma have not been described systematically.
Specific Infectious Agents
Certain infectious agents, which either precede or occur con-
comitantly with various immune-related conditions associated
with NHL, may be etiologically important.
Human immunodeficiency virus (HIV) infection. Patients
with acquired immunodeficiency secondary to HIV infection are
at 59- to 104-fold risk of NHL (42,43). The cumulative inci-
dence of NHL in HIV-infected subjects receiving antiretroviral
therapy was 29% after 36 months (44). Among HIV-related
NHL, high-grade B-cell subtypes predominate (45), especially
immunoblastic and Burkitt’s (small noncleaved) NHL (42), al-
though diffuse subtypes also occur (43).
The excess of high-grade NHL in San Francisco, particularly
Table 5. Non-Hodgkin’s lymphoma cases (all races and both sexes) in nine
SEER areas (from 1990 through 1995) by immunophenotype and histology*
Histology
No. of
cases
Immunophenotype
T cell, % B cell, %
Not specified
T or B, %
Total 25 364 5.7 33.7 60.6
Small lymphocytic
A: Small lymphocytic 2217 1.1 30.1 68.8
Follicular 4356 0.6 32.4 67.0
B: Follicular small 1948 0.5 30.2 69.4
C: Follicular mixed 1399 0.6 31.0 68.4
D: Follicular large 712 1.0 39.8 59.3
(Follicular, NOS)† 297 1.4 35.7 63.0
Diffuse 10 452 4.6 40.5 54.9
E: Diffuse small 1345 1.0 31.3 67.7
F: Diffuse mixed 1102 11.3 30.0 58.7
G: Diffuse large 7677 4.3 43.1 52.7
(Diffuse, NOS)† 328 4.0 52.3 43.3
High-grade
H: Immunoblastic 1861 7.1 41.1 51.9
I: Lymphoblastic 253 43.9 19.8 36.4
J: Small noncleaved 788 1.0 37.9 61.0
(High-grade, NOS)† 2 0.0 0.0 100.0
Peripheral T-cell 1310 38.1 6.3 55.6
NOS 4125 3.7 25.5 70.8
*SEER  Surveillance, Epidemiology, and End Results Program; NOS 
not otherwise specified.
†Subtypes within parentheses were not categorized to a specific subtype A–J
but were included in the respective major type.
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among unmarried white males, probably reflects the burden of
HIV infection (46), although incidence rates were elevated in
San Francisco whites of both sexes in earlier national cancer
surveys conducted during 1947–1948 (47) and 1969–1971 (48).
Acquired immunodeficiency syndrome (AIDS) accounts for a
relatively small fraction of NHL, however, in the total geo-
graphic regions covered by the SEER registries (17,46,49).
Hepatitis C virus (HCV) infection. Findings of a relation
between HCV and NHL are mixed. Associations of HCV with
B-cell NHL (50) and with follicular and gastric mucosa-
associated lymphoid tissue (MALT) NHL (51), but not with
intermediate- or high-grade NHL (52), have been reported in
some studies. A nationwide survey from 1988 through 1994
estimated 1.8% seroprevalence of HCV, higher in males than in
Fig. 2. Trends in age-adjusted
(U.S. population, 1970) inci-
dence rates for non-Hodgkin’s
lymphoma in nine Surveillance,
Epidemiology, and End Results
areas (from 1978–1983 through
1990–1995).
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females and in non-Hispanic blacks than in whites (53). The
etiologic role of HCV in NHL, however, is not yet well estab-
lished.
Human T-lymphotrophic virus (HTLV) types I/II. Infec-
tion with HTLV-I, especially in early childhood, is associated
with subsequent excesses of peripheral T-cell NHL in southeast-
ern Japan and in the Caribbean (54–56), but this retrovirus
causes only about 10% of mycosis fungoides and Se´zary syn-
drome in the United States (57,58). Combined HTLV-I/II infec-
tions are also exceedingly rare in the United States, with sero-
prevalence ranging from 0.03% to 4.2% in military service
applicants (59), blood donors (60,61), forensic autopsy subjects
(62), and emergency room and clinic patient populations
(63,64). U.S. intravenous drug users make up a small fraction of
the population, so even though 25% of them are infected with
HTLV-I/II (65–67), they would have a negligible effect on NHL
rates.
Helicobacter pylori. Although primary gastric lymphomas
are mostly high-grade NHL, low-grade B-cell MALT gastric
lymphomas are frequently preceded by unrecognized infection
with H. pylori (68). Eradication of the infection in early-stage
NHL can result in tumor regression (68).
Epstein-Barr virus (EBV). Post-transplant lymphoprolifera-
tive disorders (PTLDs) developing within 6 months as clinically
aggressive lymphomas of donor cell origin and NHL among
AIDS patients are thought to result from uncontrolled prolifera-
tion of EBV-transformed B lymphocytes in the setting of im-
mune dysfunction (23,69–72). The PTLDs include plasmacytic
hyperplasias, polymorphic lymphoproliferative disorders, and
frank malignant lymphomas (72). Primary immunodeficiency
disorders such as X-linked lymphoproliferative disease may also
first become manifest after EBV infection (73). Burkitt’s (small
noncleaved) lymphoma in Africa is a distinct entity arising
among children in a defined geographic belt (74). Early EBV
infection has been consistently associated with African Burkitt’s
lymphoma on the basis of epidemiologic, serologic, and molecu-
lar studies (73). Malaria has been identified as a cofactor based
on the overlapping geographic distribution, the high rates in the
same population, and reduction in both after chloroquine pro-
phylaxis (73).
In the United States, the rarity of HTLV-I, the declining
prevalence of H. pylori (75), and the ubiquity of EBV infection
suggest that these agents are unlikely to explain the increases in
NHL.
Blood Transfusions
Blood transfusions, which may transmit infectious agents and
other immune-modulating antigenic exposures, have not been
associated with NHL in a large Swedish cohort (76) or in two
U.S. studies (77,78). Thus, there is little evidence that the dra-
matic rise in blood transfusions in the last five decades (79,80)
contributed to the rising rates of NHL.
Agricultural and Pesticide Exposures
NHL has been linked with exposure to pesticides, crops, and
livestock. Italian farmers and animal breeders were found to
have twofold risks of low-grade NHL (81), and U.S. farmers had
a twofold risk of lymphocytic NHL (82). A U.S. population-
based, case–control study found small excesses of follicular
NHL among meat packaging and processing workers (83).
The use of agricultural herbicides (particularly 2,4-
dichlorophenoxyacetic acid) was associated with a notable
dose–response effect for NHL, particularly among farmers who
mixed and applied the compounds themselves (84). Herbicides
increased the risk of follicular large-cell NHL in Nebraska (85),
whereas modest increases for small lymphocytic (associated
with certain crops and pesticide categories) and diffuse (linked
with specific herbicides and pesticides) NHL occurred among
farmers in Iowa and Minnesota (86). Total U.S. pesticide use
rose from 647 million pounds in 1964 to 1144 million pounds in
1979 and then declined to 973 million pounds in 1995 (87). The
role of agricultural and residential pesticides in the etiology of
NHL requires further evaluation. The relatively small numbers
of agricultural, lawn care, and pesticide manufacturing workers
and pesticide applicators suggest that these workers account for
only a modest fraction of the NHL increase in the general popu-
lation.
Lifestyle Factors
Diet. Milk (88), red meat (89,90), and butter, liver, and ham
(91) have been associated with increased risks of NHL, whereas
fruit (particularly citrus) (88,89), carrots, and whole-grain di-
etary products (91) have been linked with reduced risks. In one
study (90), risks rose with increasing estimated serum retinol
levels and declined with increasing estimated -carotene levels.
High intake of red meat, trans-unsaturated fat, and saturated fat
was also linked with increased risks in the Nurses’ Health Study
cohort (92).
Cigarette smoking. Most large cohort and case–control stud-
ies of cigarette smoking and cancer (93–95) have detected little
effect of smoking on risk of NHL. Smoking was linked with
high-grade NHL in several case–control studies (91,96,97) and
with follicular NHL in a few cohort studies (98,99).
Hair dye. Findings are inconsistent, with small increases in
incidence of follicular NHL (100) or NHL mortality (101) as-
sociated with hair dye use (particularly black or brown dyes used
for 10 years) found in some but not in other (102,103) large
cohort or case–control studies.
UV radiation. Spatial and temporal correlations in incidence
rates for nonmelanoma skin cancer and NHL have been hypoth-
esized to support a link between solar UV radiation (UVR) and
NHL (104); the proposed mechanism involves an immunosup-
pressive effect of UVR. Swedish investigators (105) described
increased risks of NHL and chronic lymphocytic leukemia sub-
sequent to melanoma and nonmelanoma skin cancers and ex-
cesses of both types of skin cancer subsequent to NHL. In En-
gland and Wales, ambient solar UV levels have been correlated
with NHL incidence (106), and women (but not men) in outdoor
occupations were found to have an increased risk of NHL (107).
Ecologic studies (108,109) have shown NHL to be inversely,
although weakly, correlated with latitude in European but not in
U.S. Caucasians. Analytic investigations would help to clarify
whether solar UVR is associated with NHL.
Relatively few studies have addressed diet, smoking, or other
lifestyle risk factors for NHL; the effect of these exposures on
NHL risk, if any, has yet to be firmly established and seems
unlikely to explain the increasing trends.
Genetic Factors
Yunis et al. (110) found 14;18 chromosomal translocations
associated with follicular NHL, 8;14 translocations linked with
Burkitt’s lymphoma (classified here with small noncleaved
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NHL), and trisomy 12 increased in small lymphocytic NHL. The
q32 band on chromosome 14 is the most common breakpoint in
NHL (111). The t(14;18) (q32;q21) translocation, involving the
bcl-2 gene, occurs in 90% of follicular lymphomas (112) and in
some patients with non-neoplastic lymphoproliferation (113).
The increased chromosome breakages and rearrangements in-
volving 14q32 and 18q21 observed in healthy pesticide fumiga-
tors have not yet been linked with NHL characterized by t(14:
18) (q32;q21) translocations (114). The well-established,
nonrandom cytogenetic translocations or other genetic lesions
characterizing certain NHL subtypes may be associated with
different etiologies but do not explain the increasing trends.
Familial aggregation and the notable occurrence of various im-
munologic abnormalities among multiple-case family members
with and without NHL or related lymphoproliferative neoplasms
may reflect genetic factors and/or gene–environment interaction,
but such familial occurrence does not account for the rising
incidence (115).
Demographic and Temporal Variation in NHL Incidence
An earlier study (116) evaluated SEER Program NHL sub-
type-specific data (from 1973 through 1987) for all races com-
bined. Our more detailed assessment, revealing important dif-
ferences in age, sex, race, geographic, and recent trend patterns
from 1978 through 1995, suggests differing etiologies of NHL
subtypes. Data from the limited number of available analytic
studies, however, do not consistently support subtype-specific
variation in risk of NHL.
The onset of the rising NHL incidence is difficult to ascertain,
although Connecticut Tumor Registry data have shown fourfold
to sixfold increases in NHL since 1935 (117). Other U.S. NHL
data are lacking before World War II, since NHL was first
evaluated as a separate entity in the late 1940s (47) and was
initially categorized only as lymphosarcoma or reticulosarcoma
in the late 1960s (9,48).
In the consideration of patterns by histologic type, the poten-
tial impact of unclassified cases needs to be addressed. The
proportion NOS was higher among blacks than among whites,
which could reduce the true type-specific white/black rate ratios
(Table 2), but the general patterns observed are most likely real.
The higher NOS rates among middle-aged than among older
persons (Fig. 1) and the notably higher rates among males than
among females may suggest that these NOS cases were actually
aggressive high-grade lymphomas. The more rapid temporal in-
creases in NOS compared with total NHL reduces concern that
improving specificity of classification contributed to the in-
creases observed in many of the NHL subtypes.
Reasons for the increasing incidence of most NHL subtypes
are obscure, since well-established major risk factors (e.g., im-
munosuppression, autoimmunity, and HIV infection) explain, at
most, a small fraction of the cases (49,118). The increase is
larger than could be explained on the basis of changing diag-
nostic practices or misclassification (119). Only diffuse small
NHL declined, probably because of changing diagnostic practice
(120). The meteoric rise in high-grade AIDS-related lymphomas
in the 1980s constitutes only 7%–13% of all NHL in the total
geographic regions covered by SEER registries (46,49). The
rapid increase in follicular NHL among black males remains
puzzling.
New Approaches to the Classification of the NHLs
In 1994, the International Lymphoma Study Group proposed
a revised European-American lymphoma (REAL) classification
(121), with defined subgroups confirmed to have prognostic sig-
nificance (122). Newly proposed revisions of the World Health
Organization (WHO) classification of lymphomas rely heavily
on the REAL classification (123), and the new ICD-O-3 field
trial version (124) incorporates the WHO classification. Our
analysis included cases diagnosed from 1978 through 1995, and
the data have not been recoded to the new system. Immunophe-
notype is an indispensable element of this classification, but we
found specification of T- versus B-cell lacking for more than
half of NHL cases diagnosed during the 1990s. A recent review
of the epidemiology of the REAL classification subtypes of
NHL (125) illustrates the potential usefulness of this nomencla-
ture as an aid to descriptive epidemiology.
Conclusion
Our data suggest that evaluation of epidemiologic patterns of
NHL according to histologic subtype remains highly informa-
tive. While analytic studies have not consistently shown clear
variation in NHL risk factors by subtype, the small number of
such investigations does not permit firm conclusions. Future
epidemiologic studies of NHL should evaluate risk factors ac-
cording to the six major categories in this study as well as the
WHO classification, since we find major incidence variation by
age, sex, race, geographic area, and time period.
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